Brown & Brown Q2 Revenue Surges 30% on Acquisitions, but Organic Growth Stalls
BRO sits 23% above its 52-week low of $53.814.
Summary
Brown & Brown reported Q2 2026 revenue of $1.7 billion, a 30.4% increase driven entirely by acquisitions, while organic revenue declined 0.7%. Net income rose 24.7% to $288 million, and the company refinanced its credit facility and repurchased $500 million in shares.
Key Events · Earnings and Guidance · BRO
-
Revenue Surges on M&A, Organic Growth Stalls
Total revenue of $1.7 billion increased 30.4% year-over-year, driven entirely by acquisitions. Organic revenue declined 0.7%, reflecting flat underlying demand.
-
Profitability Improves Despite Organic Weakness
Net income attributable to the Company rose 24.7% to $288 million, with diluted EPS of $0.84. EBITDAC - Adjusted increased 27.0% to $598 million, aided by cost leverage and lower earn-out charges.
-
Credit Facility Refinanced, Liquidity Enhanced
On June 5, 2026, the Company entered into a Third Amended and Restated Credit Agreement, increasing revolving commitments to $1.25 billion and adding $500 million in term loans, extending maturities to 2031.
-
Aggressive Share Repurchases Continue
The Company repurchased $500 million of common stock in H1 2026, including $250 million via an accelerated share repurchase and $250 million in open market purchases. $900 million remains authorized.
Analysis · BRO · Finance
Brown & Brown's Q2 2026 results reveal a stark divergence between acquisition-driven expansion and core business performance. While total revenue jumped 30.4% to $1.7 billion, entirely from M&A, organic revenue slipped 0.7% — a warning sign for underlying demand. Profitability still improved, with net income up 24.7% and EBITDAC - Adjusted up 27%, but the organic stall raises questions about the sustainability of growth. The company also refinanced its credit facility, boosting liquidity, and continued aggressive share buybacks, signaling confidence in its stock. Investors must weigh the acquisition-fueled top-line surge against the organic weakness.
At the time of this filing, BRO was trading at $66.03 on NYSE in the Finance sector, with a market capitalization of approximately $23.6B. The 52-week trading range was $53.81 to $104.25. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.